"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

Study links hallucinogen use to higher schizophrenia risk, highlighting the need for caution and informed decisions on ...

The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...

In other news: a dramatic increase in obesity rates; standing desks may not actually be a healthier choice; laughter is effective in combating dry eye disease; and more.

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

Feeling lonely increased risk for all-cause dementia by 31 percent and cognitive impairment by 15 percent. Loneliness is a ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...

ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...

AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...